As our preliminary laboratory studies have demonstrated, the finasteride and selenium combination strategy represents a promising paradigm for prostate cancer chemoprevention. While our complementary projects aim to elucidate molecular mechanisms, we propose in this project to conduct a clinical trial to directly evaluate the chemopreventive efficacy of the finasteride and selenium combination. The proposed study is a randomized, double-blind, placebo-controlled, phase IIB intervention trial that employs a 2X2 factorial design. Patients diagnosed with early stage prostate cancer who have opted for prostatectomy at Roswell Park Cancer Institute will be recruited. The participants will be randomized to pretreatment supplementation by daily doses of 5 mg finasteride or placebo, and 400 ng selenomethionine or placebo. After 8-9 weeks of supplementation, prostate samples will be obtained during surgery. The primary goal is to assess the impact of finasteride, selenium, and their combination on androgen signaling. This will be done by examining the mRNA expression of prostate specific antigen (PSA) and kallikrein 2 (KLK2), two well-known androgen-regulated genes. A secondary goal is to evaluate apoptosis induction by finasteride and selenium. This will be done by using the TUNEL assay, immunohistochemical staining of activated caspase-3, and an ELISA-based apoptosis detection method. In addition, we will explore the hypothesis that peroxiredoxin 1 (Prx 1) interferes with the suppression of androgen signaling by finasteride/selenium, correlating the mRNA expression of Prx 1 with that of PSA. This study will provide key human in vivo data on the chemopreventive potential of the finasteride and selenium combination. The tissue specimens collected in the trial will be a valuable resource for corroborating the findings from the in vitro mechanistic studies proposed in projects 1 and 2.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Ondracek, Rochelle Payne; Kattan, Michael W; Murekeyisoni, Christine et al. (2016) Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. J Natl Compr Canc Netw 14:1395-1401
Cheng, J; Ondracek, R P; Mehedint, D C et al. (2015) Association of fatty-acid synthase polymorphisms and expression with outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis 18:182-9
Payne Ondracek, Rochelle; Cheng, Jinrong; Gangavarapu, Kalyan J et al. (2015) Impact of devascularization and tissue procurement on cell number and RNA integrity in prostatectomy tissue. Prostate 75:1910-5
Fiandalo, Michael V; Wu, Wenjie; Mohler, James L (2013) The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr Drug Targets 14:420-40
Chhipa, Rishi Raj; Halim, Danny; Cheng, Jinrong et al. (2013) The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific. Prostate 73:1483-94
Wu, Yue; Godoy, Alejandro; Azzouni, Faris et al. (2013) Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5?-reductase inhibitors. Prostate 73:1470-82
Wu, Yue; Chhipa, Rishi Raj; Zhang, Haitao et al. (2011) The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer Biol Ther 11:902-9
Chhipa, Rishi Raj; Wu, Yue; Ip, Clement (2011) AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia. Cell Signal 23:1466-72
Zhang, Haitao; Fang, Jian; Yao, Dian et al. (2010) Activation of FOXO1 is critical for the anticancer effect of methylseleninic acid in prostate cancer cells. Prostate 70:1265-73
Cheng, Jinrong; Wu, Yue; Mohler, James L et al. (2010) The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer Biol Ther 9:1033-42

Showing the most recent 10 out of 15 publications